IDERA PHARMA (NASDAQ:IDRA)

4.83

+0.14 (2.99%)

IDERA PHARMA (NASDAQ:IDRA) Delayed :
Previous Close	$4.69	52 Week High	$9.19
Open	$4.63	52 Week Low	$4.50
Day High	$5.06	P/E	96.60
Day Low	$4.62	EPS	$0.05
Volume	46,604
More IDRA Info: Chart SEC Filings Profile Historical Options

What is this?Friends, Peers and Foes

Ticker	# Stories	Ticker	# Stories
MRK	1

View All Entities

Nov 5, 2009 08:12 AM Idera Pharma (IDRA) Posts Break-Even Q3 EPS, Down 8c from Q308

Nov 5, 2009 08:12 AM Idera Pharma (IDRA) Posts Break-Even Q3 EPS, Down 8c from Q308
Nov 3, 2009 09:50 AM Idera Pharma (IDRA) Presents IMO-2125 Preclinical Data
Oct 26, 2009 09:55 AM Idera Pharma (IDRA) Announces TLR Patent Issuance
Oct 19, 2009 09:55 AM Idera Pharma (IDRA) to Present Preclinical Data from IMO-3100 Studies at ACR/ARHP Meeting
Oct 7, 2009 09:24 AM Phase 1 Initiated by Idera Pharmaceuticals (IDRA) to Evaluate IMO-215 in Combination with Ribavirin for Chronic Hep. C Virus

Nov 3, 2009 08:00AM Idera Pharmaceuticals Presents Preclinical Data on IMO-2125, its Lead Drug Candidate for Chronic Hepatitis C Virus Infection, at Liver Meeting 2009
Oct 26, 2009 08:00AM Idera Pharmaceuticals Announces Issuance of Patents Covering its Novel Toll-like Receptor-Targeted Compounds and Their Use
Oct 19, 2009 09:00AM Idera Pharmaceuticals Presents Preclinical Data at ACR/ARHP 2009 Annual Meeting on IMO-3100, a Toll-Like Receptor Antagonist, in Combination with Enbrel(R) in Arthritis Model
Oct 16, 2009 08:00AM Idera Pharmaceuticals to Present at 8th Annual BIO Investor Forum
Oct 7, 2009 08:00AM Idera Pharmaceuticals Initiates Phase 1 Clinical Trial of IMO-2125, a TLR9 Agonist, in Combination with Ribavirin for Chronic Hepatitis C Virus Infection

Nov 18, 2009 04:41 PM Biotech Stocks for a Possible Year-End Rally
Sep 20, 2009 04:50 PM Spectrum Pharmaceuticals: Despite Share Offering, Still Cheap vs. Other Cancer Drugmakers
Sep 11, 2009 05:49 AM Spectrum Pharma: Post-Zevalin Approval Sales Should Ramp Up

No comments are currently available.